Skip to main content
. 2018 Jan 10;9(12):10723–10733. doi: 10.18632/oncotarget.24112

Figure 5. Yes inhibitors block NF2-deficient PRCC cell cycle.

Figure 5

Quantification of UOK275 (A) and HEK293 (B) cell cycle phases by BrdU and propidium iodide (PI) staining. The panels display the position of gates used to quantify cells in G0-G1, S or G2-M phases after 18 hours of treatment with DMSO (control), or dasatinib (50 nM or 500 nM). (C) Quantification of cells in the different cell cycle phases in HEK293, UOK275, UOK342 and ACHN after DMSO or dasatinib treatment (average of 3 distinct experiments).